First immunotherapy to treat advanced endometrial cancer on the NHS via Cancer Drugs Fund

pharmafile | February 8, 2022 | News story | Manufacturing and Production  

GSK has shared that NICE is to issue a final appraisal determination (FAD) recommending the use of JEMPERLI®▼ (dostarlimab) via the Cancer Drugs Fund (CDF) as a treatment option for patients with a common and aggressive form of advanced endometrial cancer.

Endometrial cancer is a cancer of the womb lining. This decision makes dostarlimab available via the CDF for adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer, whose cancer has progressed on or following prior treatment with a platinum containing regimen (a type of chemotherapy).

“To date, beyond chemotherapy, there have been limited treatment options for women with advanced, recurrent endometrial cancer in England,” said Dr Susana Banerjee, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust. “The decision by NICE changes that, providing the opportunity for patients whose cancer has a specific abnormality called MSI-H or MMR deficiency to access immunotherapy with dostarlimab. The NICE decision is a step forward in improving outcomes for women with endometrial cancer by delivering tailored treatment.”

There are around 7,700 new cases of endometrial cancer each year in the UK, of which an estimated more than 170 women could be eligible for treatment with dostarlimab – increasing their chance of stabilising or slowing the progression of their disease

Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. It is the most commonly diagnosed gynaecological cancer in the UK, and is the 7th most common cause of cancer death in the UK. The prognosis for patients diagnosed with advanced/recurrent endometrial cancer is extremely poor.

The median overall survival of women with recurrent, advanced endometrial cancer is reported to be less than 12 months with only 15% of women diagnosed with late-stage disease surviving for 5 years or longer. Prior to this decision, there was no standard of care for patients with advanced or recurrent endometrial cancer once they have progressed on or after platinum-containing chemotherapy.

Ana Ovey

Related Content

No items found

Latest content